Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion of medicines. This pause impacts a public health initiative.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oqNlEpf
via IFTTT

Read More

Lord's Mark Industries Ltd. announces AI-supported Dialysis ecosystem launch

Lord's Mark Industries Ltd. has launched an integrated dialysis ecosystem in Ahmedabad, featuring the AI-driven Renalyx Machine. This CE-certified, India-engineered system, coupled with RenalOS and Aureoon, offers a Dialysis-as-a-Service model. It aims to provide accessible, affordable, and advanced renal care by eliminating capital investment for hospitals and focusing on patient-centric, continuous treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PVAFZfB
via IFTTT

Read More

Novartis expands India role in global drug development

Novartis is focusing on innovative medicines in India. The company is expanding its role in global drug development. Early-stage research is now happening in India. Novartis plans to launch more new medicines soon. This strategy reinforces its commitment to the Indian market and its significant employee base.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NHjQ6fq
via IFTTT

Read More

Biocon arm gets Health Canada nod for fungal infection treatment injection

Biocon Pharma Ltd has secured Health Canada approval for its micafungin for injection. This medication targets serious fungal infections in adults and children. It will be used for conditions like candidemia and esophageal candidiasis. The approval also covers prophylaxis in stem cell transplant patients. This marks a significant addition to Biocon's product offerings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A9j4ngD
via IFTTT

Read More

Drugmakers must report safety data from launch date, not approval date: CDSCO

India's drug regulator has issued a new directive for pharmaceutical companies. Periodic Safety Update Reports for new drugs must now be submitted from the actual market launch date. This change aims to strengthen patient safety monitoring. Previously, reports were based on the regulatory approval date. The new rule ensures that real-world data from patients is included.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/grlCBG9
via IFTTT

Read More

India's hospital sector enters new growth cycle as AI and capacity expansion reshape care: Report

India's hospital sector is set for significant growth over the next decade. Demand is rising due to increased income, insurance, an aging population, and chronic diseases. Hospitals are expanding capacity to meet a critical bed shortage. Private insurance is growing, boosting revenue. This expansion offers substantial opportunities for investors and operators in the healthcare industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mWBKsXV
via IFTTT

Read More

EQT emerges sole bidder for OmniActive Health Technologies

Swedish investment powerhouse EQT is now leading the charge as the exclusive bidder for OmniActive Health Technologies, following the rejection of a competing offer from Temasek and Novo Holdings. Known for its robust presence in the nutraceutical industry, OmniActive is under the umbrella of TA Associates and has a strong export footprint in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/91pvszd
via IFTTT

Read More

MSD India ropes in Madhuri Dixit for cervical cancer awareness drive

US pharma major MSD has partnered with Bollywood actor Madhuri Dixit for a nationwide cervical cancer awareness program in India. The initiative aims to encourage conversations about women's preventive healthcare and prompt discussions with doctors regarding cervical cancer and its prevention. Digital films featuring Dixit have been released to amplify the campaign's reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EPz24lq
via IFTTT

Read More

Hantavirus outbreak on cruise ship: India monitors situation, no cases on Indian soil

The Union Health Ministry is monitoring hantavirus cases on the cruise ship MV Hondius, where three deaths and five confirmed infections have occurred. India has no domestic cases and its surveillance networks are active. The Andes strain, with limited human-to-human transmission, has been identified, and the WHO assesses the public health risk as low.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yKRBPXu
via IFTTT

Read More

India faces no immediate public health threat from hantavirus: NIV chief

Two Indian nationals aboard a cruise ship have reportedly contracted hantavirus. Indian health officials assure the public that these cases appear isolated. There is no immediate public health threat to India. Experts confirm hantavirus does not spread easily among people. India possesses adequate laboratory capacity for diagnosis. Standard rodent control and sanitation remain key preventive measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gkVsenY
via IFTTT

Read More

Semaglutide race: Torrent grabs 38% market share

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of Novo Nordisk's patent for the innovator molecule in end-March. They generated about ₹44 crore in generic semaglutide sales in April.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MRljJ4P
via IFTTT

Read More

Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition space

Dr Reddy's teams up with Nestle Health Science to introduce Celevida GLP+, a specialized supplement crafted for those navigating the challenges of GLP-1/GIP therapy for type 2 diabetes and obesity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/shVKNgM
via IFTTT

Read More

Venus Remedies expands Latin America presence with Argentina nod for antibiotic

Venus Remedies has received approval in Argentina for its antibiotic Ceftriaxone. This marks a significant step in the company's Latin America expansion. Argentina is a key market for critical care therapies. Ceftriaxone is vital for treating serious bacterial infections. This authorization strengthens Venus Remedies' global presence and commitment to accessible anti-infective treatments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x1SmKLv
via IFTTT

Read More

Sun Pharma gets relief in trademark case from High Court

The Bombay High Court has ruled in favour of Sun Pharmaceutical Industries. The court has restrained United Biotech from using a similar trademark. Sun Pharma's 'Octride' mark is protected. The dispute involves drugs for acromegaly and carcinoid tumours. The court found Sun Pharma had a stronger claim. This decision protects Sun Pharma's reputation and goodwill.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bCipSD7
via IFTTT

Read More

Kiran Mazumdar-Shaw picks niece Claire as successor at Biocon

Biocon's founder Kiran Mazumdar-Shaw has made a groundbreaking announcement, pledging her niece Claire Mazumdar as her heir apparent. The transition plan is designed for a slow handover while Mazumdar-Shaw remains at the helm.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VeLKuyd
via IFTTT

Read More

Emcure eyes India growth, global deals amid strong demand

Emcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in India and internationally. New products are expected to drive significant growth. Emcure's partnership with Novo Nordisk for GLP-1 therapies and a pipeline of complex injectables will support future momentum.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pz5h9Rg
via IFTTT

Read More

The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garage

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who built the company from a garage into a global biotech leader, Kiran is ensuring continuity by handing over to a science-driven leader while remaining at the helm during the transition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5aD4IzM
via IFTTT

Read More

Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: Report

Biocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder and CEO of Bicara Therapeutics. She holds advanced degrees and has prior industry experience. Biocon is also undergoing structural changes. The company focuses on biosimilars and integrating artificial intelligence. Other leadership transitions are also in progress across group companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7IeS5jn
via IFTTT

Read More

Pharma exports surpass $31 billion in FY26 despite global headwinds

Indian pharmaceutical exports reached over $31 billion in FY26. March saw a significant 23% drop, primarily due to a slowdown in the United States and China. However, other markets like Africa and Oceania showed strong growth. Vaccines emerged as the fastest-growing export category. The industry is navigating challenges in key markets while exploring new growth avenues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cm9AgZw
via IFTTT

Read More

Carlyle acquires Knack RCM and Equalize RCM to create an AI-native, global multi-specialty healthcare RCM platform

Global investment firm Carlyle has acquired a majority stake in US healthcare revenue cycle management providers Knack RCM and EqualizeRCM. This move aims to create a global, AI-native, multi-specialty RCM platform. The combined entity will leverage AI and global delivery to enhance operational scale and client outcomes, addressing critical financial risks for healthcare providers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iHPezoQ
via IFTTT

Read More

Two separate venues for pharma industry expos in Delhi-NCR

CPHI India and PMEC India are expanding their pharmaceutical expos to two venues in Delhi-NCR. This move aims to support the rapid growth of India's pharma sector. The events will offer greater business engagement and specialized networking. CPHI India will focus on ingredients and formulations. PMEC India will showcase machinery and manufacturing technologies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Uh081QY
via IFTTT

Read More

Bombay HC backs GSK in Paxil trademark row against Shreya Life Sciences

The Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medicinal preparations. It argued that despite getting the mark more than two decades ago, Shreya Life Sciences had never used it and hence, under Section 47 of the Trade Marks Act, the registration was liable to be removed from the register of trade marks on account of non-use.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9tGdrAP
via IFTTT

Read More

Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilar

Aurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health Canada for its cancer drug Bevqolva. This approval marks a crucial step for the bevacizumab biosimilar. Bevqolva is used to treat various cancers. Health Canada's nod confirms its safety and efficacy. This opens new avenues for cancer treatment in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4Zb1YWw
via IFTTT

Read More

Drugs at your door: Signs of a disruption taking shape in India

India Pharmacy Retail Quick Commerce: India's medicine delivery is seeing a change. Quick-commerce apps are making it easier to buy medicines regularly. While total sales are not growing much, people are buying more wellness products. Acute care medicines are seeing fewer sales. This shift is happening as more people shop online for health items. The market is changing, not booming yet.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WA1ktfa
via IFTTT

Read More

ORS sales melt in March after govt's stricter labelling norms

India’s oral rehydration solution (ORS) market has declined after regulatory action restricted the labelling of sugary drinks as ORS, affecting pharmaceutical companies that depend on seasonal demand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1hk20ED
via IFTTT

Read More

RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-September

RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0UcztMm
via IFTTT

Read More

Weight-loss drugs may also help cut alcohol intake: Study

A new study shows GLP-1 drugs like semaglutide may help reduce heavy drinking. A trial found weekly injections cut heavy drinking days by half. This drug, also used for obesity, showed significant results in adults with alcohol use disorder. The findings could impact millions globally. Further research is ongoing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Rw2p4TY
via IFTTT

Read More

KKR invests Rs 1,750 cr in Baby Memorial Hospital

KKR, the prominent US investment firm, has committed another ₹1,750 crore to Baby Memorial Hospital, elevating their overall investment to an impressive ₹5,100 crore in just a short span of two years. This Kozhikode-centered hospital chain is poised for significant regional growth. The capital will facilitate strategic acquisitions and further expansion, now boasting nine hospitals spread across three southern states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/neIgkx6
via IFTTT

Read More

IHH-Daiichi legal battle nears verdict on September 10

A major legal battle between IHH Healthcare and Daiichi Sankyo is reaching its climax. IHH's subsidiary, NTK, is seeking JPY 200 billion in damages. The Tokyo District Court will deliver its judgment on September 10. This ruling follows NTK's allegations of Daiichi Sankyo obstructing its acquisition of Fortis Healthcare shares.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/blz1ODJ
via IFTTT

Read More

AHH names Venkatesh Tarakkad as CFO; Ritesh Pandey moves to chief business officer role

Asia Healthcare Holdings has appointed Venkatesh Tarakkad as its new Chief Financial Officer and Head of Business Development. Tarakkad brings over three decades of experience in finance and mergers. He previously served as CFO at UpGrad. This appointment supports AHH's growth strategy. Ritesh Pandey moves to Chief Business Officer for new initiatives. AHH operates specialty healthcare brands across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JILmQ0b
via IFTTT

Read More

Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma deal

Sun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acquisition ever by an Indian pharmaceutical company. The deal values Organon at $14 per share and gives Sun Pharma a major global expansion boost, including entry into the US women’s healthcare market and stronger presence across key international regions such as China, Europe, Korea, and Latin America.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GNqISso
via IFTTT

Read More

Organon gives Sun Pharma scale and reach, but challenge lies in integration, execution

Sun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It also offers diversification into new segments like women's health and biosimilars. The acquisition is expected to strengthen Sun Pharma's position for future growth. Managing integration and debt will be key.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LVzPnCv
via IFTTT

Read More

Sun Pharma: How a small Kolkata trader became a global buyout artist

Sun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continues Shanghvi's proven strategy of acquiring companies to fuel growth and global expansion. His approach prioritizes strategic advantage and turnaround potential, as seen in past landmark deals like Ranbaxy and Taro.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fX9BkGL
via IFTTT

Read More

Robotic joint replacement surgery and insurance: The gap patients should know about

Robotic surgery offers better outcomes for knee pain patients. However, many Indians cannot access this advanced treatment due to insurance limitations. Insurers should update policies to cover robotic procedures equally with traditional ones. This will improve patient recovery and reduce long-term healthcare costs. Aligning insurance with medical progress ensures better healthcare for everyone.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rM0dKRt
via IFTTT

Read More

ET Awards: Cyrus Poonawalla reflects on SII’s mission of affordable vaccines and saving lives worldwide

Cyrus Poonawalla began Serum Institute of India in 1966 with a goal to make India self-reliant in healthcare. His vision was to provide affordable vaccines and save lives. The institute has since become a global leader, supplying vaccines to over 100 countries. It played a crucial role during the Covid-19 pandemic. Poonawalla hopes his son Adar will continue this mission.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wuhJGK2
via IFTTT

Read More

Sun Pharma to buy Organon in $11.75 billion all-cash deal

Sun Pharmaceutical Industries has agreed to acquire U.S. drugmaker Organon & Co in an all-cash deal valued at approximately $11.75 billion, including debt. The agreement stipulates Sun Pharma will purchase all outstanding Organon shares for $14.00 per share. This acquisition will grant Sun Pharma full ownership of Organon, a company focused on women's health, biosimilars, and established medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d54ys7m
via IFTTT

Read More

ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till date

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai HQed company pips the consortium of EQT-Gruenthal. Sun will pay $4.5 billion for Organon’s equity and inherit $8.5 billion of its debt.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xykj689
via IFTTT

Read More

SC asks states, UTs to prepare action plan to implement guidelines for intensive care services

The Supreme Court has directed all states and Union Territories to develop realistic action plans for implementing minimum ICU standards. An expert-prepared guideline document will be shared, with a focus on identifying and prioritizing five essential manpower and equipment requirements. A compliance and monitoring mechanism is also mandated, with a three-week deadline for a final report.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SFvyPDt
via IFTTT

Read More

Sun Pharma looks to outshine rival bids with $13 billion Organon offer

Sun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the Indian drug giant into a global leader in branded and innovative medicines. Sun Pharma is competing with other major players for the US company. The deal, if successful, would see Organon merge with Sun Pharma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oLTDs8N
via IFTTT

Read More

Sun Pharma wins trademark case against Navi Mumbai company

The Bombay High Court has ruled against a Navi Mumbai drugmaker. The court prohibited the use of brand names 'Absun' and 'Absun Pharma'. This decision favors Sun Pharmaceutical Industries in a decade-long trademark dispute. The court found the names deceptively similar to Sun Pharma's established marks. The ruling prevents confusion among consumers in the pharmaceutical market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c7O6z2v
via IFTTT

Read More

Premji Invest takes stake in NewEra Hospitals to expand capacity, strengthen advanced care network

Premji Invest is backing NewEra Hospitals with a new investment. This funding will help NewEra expand its hospital capacity to 800 beds. The platform will also scale advanced specialty care across Maharashtra. NewEra currently operates three hospitals with 350 beds. The company plans to add three more hospitals in Nagpur. This expansion aims to improve access to high-complexity medical care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y2s1A8X
via IFTTT

Read More

Different packaging, typos expose fake Mounjaro racket

Gurugram authorities uncovered a counterfeit Mounjaro operation. Police seized fake diabetes and weight loss injections valued at ₹70 lakh. The alleged mastermind, Avi Sharma, procured raw materials from China. The investigation revealed significant differences in packaging and typographical errors on the fake products. Sharma was arrested for producing these illicit drugs to increase his income.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cHDJheB
via IFTTT

Read More

Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosol

Pharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks a significant milestone for Cipla, reinforcing its leadership in the respiratory segment. The approval enhances Cipla's US portfolio, offering a therapeutic equivalent to a key branded medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2C6WKwh
via IFTTT

Read More

USFDA issues Form-483 with 5 observations to Ajanta Pharma's Paithan facility

Ajanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra from April 13–21, 2026. The company stated it will respond within the stipulated timeframe, while noting that Form-483 is issued when inspectors observe potential regulatory violations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WjGbXS1
via IFTTT

Read More

Lupin launches generic anti-diabetic tablets in US

Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydrochloride extended-release tablets. The US Food and Drug Administration approved the drug. Lupin's product is bioequivalent to Xigduo XR. This launch offers a new treatment option for diabetic patients in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hzWucXo
via IFTTT

Read More

Govt's ammonia rule to hurt pharma cos as directive restricts sale of surplus to fertiliser firms

India’s pharmaceutical industry faces a potential raw material crunch after the government restricted surplus ammonia supply to fertiliser use. Drugmakers warn the move could disrupt API production, cause medicine shortages and impact exports, as ammonia is a critical input and alternative sourcing options remain limited.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ydy0Mio
via IFTTT

Read More

Obesity drug market to gain as Indians pop the pill and Chinese bring more

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, will soon be available. These pills offer a cheaper and easier alternative to injections. Experts anticipate greater patient adoption due to convenience and affordability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3cnR9DY
via IFTTT

Read More

Counterfeit Mounjaro case: Eli Lilly issues statement after Gurugram drug racket exposed

Gurugram's law enforcement has taken a bold step by breaking up a ring creating counterfeit Mounjaro injections, with two individuals now in custody for their role in the illicit trade of diabetes and obesity medications. The illicit enterprise involved importing raw materials from China and manufacturing the injections in a private home.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5N0ywz8
via IFTTT

Read More

Bain Capital sole contender for Vitabiotics buy

TPG, EQT chose to opt out from final bids. UK’s largest nutraceutical company with operations in India, UK, China exports to 100 countries. Company was originally valued at £900 mn.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/841t3eO
via IFTTT

Read More

Drug regulator oversight sought for nutraceuticals; NGO flags quality, pricing concerns

A Gujarat NGO is pushing the government to regulate nutraceuticals like medicines. They cite concerns about product quality and unregulated prices. The NGO wants these health supplements to be overseen by drug regulators, not food safety authorities. This move aims to ensure better standards and fair pricing for consumers across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lYkuRW7
via IFTTT

Read More

Weight-loss drug craze for Ozempic, Mounjaro surges in India amid safety concerns

In India, appetite for weight-loss drugs is on the rise, with consumers increasingly turning to injectables such as Mounjaro and Ozempic for gradual weight reduction. Healthcare professionals are urging the need for stringent regulations to prevent misuse and improper marketing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bomlCn8
via IFTTT

Read More

India medical tourism slips below pre-Covid peak amid geopolitics, visa delays and rising Asian competition

India's medical tourism is facing challenges. Arrivals have dropped significantly below pre-Covid levels. Geopolitical tensions and visa delays are impacting the sector. Competition from other Asian nations is also a factor. Industry leaders suggest focusing on high-tech, reliable healthcare delivery to attract international patients. Improvements in ties with Bangladesh could help reverse the trend.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cqGQXyS
via IFTTT

Read More

Poonawalla's clear shot at access for all via route social

Cyrus S Poonawalla, chairman of Serum Institute of India, has created a legacy where business and social impact go hand in hand. His vaccines have saved over 30 million lives worldwide. The institute's founding values of affordability, quality, and access continue to guide its global efforts. The Villoo Poonawalla Foundation also drives philanthropy in healthcare, education, and community development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zf6gNs4
via IFTTT

Read More

Mankind Pharma’s Rx for success: Aatmanirbhar push, affordable care

Mankind Pharma, guided by Ramesh and Rajeev Juneja, is a leading Indian pharmaceutical firm. The company focuses on mass-market drugs and has expanded into chronic and specialty treatments. With over 75% of manufacturing in-house, Mankind Pharma emphasizes quality, affordability, and accessibility. They are investing in innovation and digital capabilities to meet growing healthcare needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gnfC5sd
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic cancer, arthritis injection

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its generic methotrexate injection, used to treat multiple cancers and arthritis conditions. The approval covers key dosage formats and confirms therapeutic equivalence to the reference drug by Hospira, enabling Alembic to market the injectable in the US. Methotrexate is widely used for treating cancers such as leukemia, osteosarcoma and breast cancer, as well as conditions like rheumatoid arthritis and severe psoriasis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gCi15TF
via IFTTT

Read More

Eye on aspirational India, medical tourism, Max Healthcare steps up bed capacity expansion

Max Healthcare Institute Ltd is expanding capacity to 10,000 beds over the next 3–4 years, investing ₹4,000–5,000 crore to meet rising domestic demand and boost medical tourism.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tGoLmXP
via IFTTT

Read More

Dr Reddy's gets nod to roll out generic oral semaglutide drug

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to Novo Nordisk's oral semaglutide (Rybelsus brand). Based on this clinical evidence, our product has received regulatory approval in India under the biosimilar regulatory pathway," a company spokesperson said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ni8MIN3
via IFTTT

Read More

Iran war impact: Essential drugs may cost up to 5% more, for now

The immediate net consumer impact could be 3-5% higher prices, or roughly similar to what consumers paid before the late-September cuts in GST rates. The industry expects the price increase to be in place for 3-4 months, with a rollback option once input costs stabilise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eh2Jf8A
via IFTTT

Read More

KKR-backed Baby Memorial to acquire 60% stake in Star Hospitals for ₹1,800 crore

Baby Memorial Hospital will acquire around 60% stake in the Hyderabad hospital chain's parent company, Unimed Healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c2ByIzk
via IFTTT

Read More

PM's AYUSH Premium Mark push sparks rise in global demand for 'Made in India' homeopathy: Experts

India's homeopathy sector is experiencing a significant surge in demand, both domestically and internationally. This growth is attributed to the government's AYUSH Premium Mark and NABL accreditation initiatives, which have enhanced quality assurance and global credibility for "Made in India" medicines. These certifications are fostering trust and enabling Indian companies to compete effectively in regulated markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CJG1U4F
via IFTTT

Read More

Bajaj Group enters healthcare: Rs 2,500 crore investment for integrated network

The Bajaj Group is entering the healthcare sector with an initial investment of Rs 2,000-2,500 crore to build Bajaj Integrated Health Systems (BIHS). This new entity will focus on an integrated continuum of care, including hospitals, day clinics, and home services, aiming for a pan-India footprint within 10-15 years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fvcnxb7
via IFTTT

Read More

Marengo Asia Hospitals aims to raise ₹500 cr via 10% stake sale

Marengo Asia Hospitals is seeking to raise ₹500 crore by selling a 10% stake, valuing the company at approximately ₹5,000 crore. The hospital chain, backed by Samara Capital and promoter families of Godrej and Havells India, operates eight hospitals across multiple regions. The funds will be used to further expand its network through acquisitions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Km6eEhx
via IFTTT

Read More

India Pharma 2026 event: Nadda lays out road map for India to take global pharma leadership role

India Pharma Conference: India is set to become a global leader in advanced medicines like biologics and biosimilars, Union Minister J P Nadda said, underlining the need for stronger research and investment. The government is implementing initiatives like Biopharma SHAKTI and PLI schemes to boost domestic manufacturing and self-reliance, he further said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5mztojw
via IFTTT

Read More

Jhunjhunwalas-backed IKS healthcare looks to acquire TruBridge for $600 million

Nasdaq-listed company will be largest buyout for tech company till date. Will give boost for revenue cycle management offerings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yDOeBAi
via IFTTT

Read More

High Court relief to Sun Pharma, Ahd Co barred from using 'Esiraft'

Sun Pharmaceutical Industries has received a significant legal victory. The Bombay High Court has stopped Meghmani Lifesciences from using its product mark 'Esiraft'. This decision comes after Sun Pharma alleged trademark infringement and passing off rights concerning its brand 'Raciraft'. The court found the marks visually and phonetically similar, likely to cause confusion among consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y7qcWhH
via IFTTT

Read More

Retatrutide: Can this shot make you lose weight & live longer, too?

A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a potential breakthrough for diabetes and obesity. Experts believe it could also contribute to longevity goals. Clinical trials show significant weight loss. Retatrutide's unique triple-action mechanism sets it apart from existing treatments, promising a new era in metabolic health management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RrFC03W
via IFTTT

Read More

Pharma and healthcare companies to face continued margin pressure: HDFC Securities

The Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the March quarter, according to a brokerage report by HDFC Securities. "We project sales/EBITDA growth of 11%/6% YoY for our coverage universe," the brokerage added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ys0ISVq
via IFTTT

Read More

Tiny hearts, big cardiac concern in India

A screening program in Raipur, Chhattisgarh, has found over 100 children with heart defects. Sixteen have undergone surgery, with more planned. This initiative, Project Dhadkan, aims to detect hidden heart risks early. Experts estimate many Indian children are born with such conditions. Early detection and treatment are crucial for normal lives. The program offers free screening and surgeries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KXrmtd8
via IFTTT

Read More

Sun Pharma closes in on Organon buy, gets set for $12 billion binding bid

Due diligence is complete, financing banks & advisors picked for biggest cross border pharma M&A by Indian pharma company. 2 other global suitors in fray.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U9kjgaM
via IFTTT

Read More

Iran conflict: Pharma supply chains may take months to recover

The recent ceasefire in the Iran conflict is a much-needed breath of fresh air for India's pharmaceutical sector, potentially rejuvenating exports. Nevertheless, industry specialists warn that it may take considerable time for supply chains to fully recover. Although raw material costs are projected to decrease slowly, West Asia remains a crucial market for Indian generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/76iNWdS
via IFTTT

Read More

Drugmaker Granules to tighten oversight after US FDA warning, executive says

The company, which is globally one of the largest paracetamol makers and a major player in the active pharmaceutical ‌ingredients market, derives ⁠a ⁠bulk of its revenue from the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/40fa8S5
via IFTTT

Read More

Govt ramps up feedstock supplies to pharma sector amid West Asia disruptions

India's government is boosting petrochemical feedstock for drug makers. This ensures essential medicines remain available as global supply chains face disruptions. Indian refiners are now supplying key inputs like propylene, ammonia, and methanol. Customs duties have also been reduced to ease costs. Domestic drug prices are stable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0FEKg3b
via IFTTT

Read More

Indian drugmaker Granules to tighten oversight after US FDA warning, exec says

Amid growing scrutiny from the U.S. FDA over documentation practices and contamination issues, Granules India is reinforcing its manufacturing framework. The company is turning to advanced digitization and automating record management to bolster data accuracy and compliance. By instituting these reforms, Granules India is proactively tackling regulatory challenges while ensuring excellence in product quality across all facilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xRD2gdE
via IFTTT

Read More

Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakers

India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. This is impacting Eli Lilly's drug sales. The market is expected to grow significantly. Indian drugmakers are launching these affordable alternatives rapidly. This marks a new era for obesity treatments in the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cHqPBxZ
via IFTTT

Read More

Centre to soon set up a digital portal to track narcotic drugs

The proposed platform will enable real-time, end-to-end digital tracking of all regulated pharmaceutical products, covering every stage from manufacturing or import through distribution, stock management and sale.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7iS8BnK
via IFTTT

Read More

IHH Healthcare aims to hike its stake in Fortis to 50%: CEO Prem Kumar Nair

IHH Healthcare sees India as a major growth market. The company plans to increase its stake in Fortis Healthcare. IHH aims to expand its hospital bed count to 10,000 by 2030. Investments will focus on existing Fortis locations and integrating Gleneagles facilities. The group is also repositioning its diagnostics arm.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8tTCAmY
via IFTTT

Read More

Biocon rolls out two biosimilars in US market

Biocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They are now available through specialty pharmacies and healthcare providers. The US Food and Drug Administration previously approved them. This launch expands Biocon's portfolio and aims to provide affordable treatment options for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CptEBOD
via IFTTT

Read More

Corporate India brings health intelligence to the fore as preventive care surges: Report

A wave of change is sweeping through Indian businesses as they embrace the significance of employee health. The rise in annual medical screenings and a boost in doctor consultations signify this shift. Young adults, particularly those from Gen Z and the millennial cohort, are at the forefront of this health revolution, demanding mental wellness support as a vital employee benefit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G3xhKLU
via IFTTT

Read More

AI in Pharma: How India's Drug Giants Are Betting Big on Artificial Intelligence

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j8et63G
via IFTTT

Read More

Capital with purpose: How capital markets are shaping the future of medicine with Dheeraj Chinthalapelly

Dheeraj Chinthalapelly, with a decade and a half of experience in global capital markets, shares his journey navigating the biotech investment banking, highlighting his focus on capital raising and mergers and acquisitions. He emphasises the importance of advising companies that bring scientific innovation to patients, navigating the evolving biotech capital markets, and prioritising long-term value creation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FeMcGX5
via IFTTT

Read More

Gut response! After protein, it’s fibre’s moment on the shelf

Social media is buzzing with 'maxxing' diet trends, focusing on extreme protein and fiber intake for better health. While these nutrients are important, experts warn that more is not always best. Companies are capitalizing on this, but a balanced approach is key. Consult a doctor for personalized advice. Real food remains the best source for optimal well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lxGvDZi
via IFTTT

Read More

Grey Market: India is ageing faster than its care systems can keep up. A new wave of startups is trying to bridge that gap

A growing number of cases of memory loss and dementia are highlighting India’s lack of early intervention and eldercare support, as the country faces a rapid rise in its ageing population. India has nearly 100 million people above 60, a number expected to exceed 300 million by 2050.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nw4mtSz
via IFTTT

Read More

Work on reducing import dependence for raw materials: Commerce Secretary Rajesh Agrawal to pharma industry

Commerce Secretary Rajesh Agrawal has called on India's pharmaceutical sector to boost domestic production and reduce reliance on imported raw materials. He emphasized diversifying export markets to navigate global uncertainties. Agrawal stressed the need for India to become a global hub for quality and cost-effective medicines. The focus is on innovation and moving towards a value-driven industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/b1sWjxl
via IFTTT

Read More

Lalitpur Pharma Park gets export push as UPSIDA, JNPA sign pact

Uttar Pradesh State Industrial Development Authority and Jawaharlal Nehru Port Authority have partnered. This agreement aims to make the Lalitpur Pharma Park a global export hub. The collaboration will connect northern India's industrial regions to international markets. This strategic move will boost pharmaceutical exports and imports. It will also enhance logistics for manufacturers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nNlDrgw
via IFTTT

Read More

India’s pharma exports stay resilient amid global headwinds, near $29 billion mark

Indian pharmaceutical exports are performing strongly. Shipments neared $29 billion by February this financial year. This growth continues despite global market volatility. Formulations, biologicals, vaccines, and Ayush products are leading the surge. The sector is poised for significant expansion by 2030. India remains a vital global supplier of affordable medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G42yv0f
via IFTTT

Read More

Govt orders safety review of popular weight-loss drugs amid rising demand

Indian authorities are increasing vigilance on popular weight loss drugs. The Indian Pharmacopoeia Commission will now compile reports on adverse events. This move aims to ensure safety and timely action. Generic versions of these drugs are expected to become widely available soon. Regulatory bodies are also cracking down on misleading advertisements for prescription medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zVMvPFC
via IFTTT

Read More

Why healthcare access still depends on affordability in India, and how universal insurance may change that

India's healthcare system faces affordability challenges despite infrastructure advancements, with out-of-pocket spending causing financial stress. Universal health insurance and digital integration are crucial for equitable access, preventive care, and a patient-focused model. Expanding infrastructure beyond metros and adopting holistic approaches are key to reducing inequality and improving outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UlEN6cY
via IFTTT

Read More

India's 'Mounjaro brides': Weight-loss injections become part of pre-wedding preparation

With wedding season in full swing, Indian health clinics are rolling out specialized weight-loss packages that include popular drugs such as Mounjaro and Wegovy. This emerging trend underscores the immense societal pressure to achieve a perfect look in a short span of time.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6JtLMfi
via IFTTT

Read More

Indian pharma sector faces supply risk amid West Asia conflict despite duty waiver

India's pharmaceutical industry faces ongoing concerns about securing essential petrochemical supplies due to the West Asia conflict. While a customs duty waiver offers some cost relief, industry experts highlight supply chain disruptions and timely movement as the primary challenges. The government's intervention aims to stabilize supply and lower input costs for critical sectors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rDa190b
via IFTTT

Read More

Emcure cuts semaglutide injection price by average 47%

The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg with the highest dose priced at Rs 8,999 for a month’s supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VXiEGxC
via IFTTT

Read More

Emcure slashes prices of weight management drug Poviztra by up to 55%

Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by up to 55 percent. This change begins on April 3, 2026. The aim is to help more people manage obesity. This move supports Emcure's commitment to better health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQmNeiH
via IFTTT

Read More

Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk

The US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Novo Nordisk in the GLP-1 medicine market. Foundayo is an oral medication offering a new option for weight management. Lilly plans to launch the pill soon, with further global approvals expected this year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VD9kGBq
via IFTTT

Read More

Govt cracks down on GLP-1 drugs: Safety first amid weight-loss hype

India's government has released strict rules for GLP-1 drugs, used for diabetes and obesity. These powerful medications are now prescription-only, requiring specialist doctors. Unsupervised sales are banned. Inspections are increasing, with penalties for rule-breakers. Patients must use these drugs only under medical care to avoid side effects. This move ensures safe use and protects public health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tRfbqPg
via IFTTT

Read More

'Allocate key chemicals to avert drug shortages', says Pharmexcil amid West Asia war

Indian drug makers face a critical shortage of essential raw materials. Pharmexcil has asked the government to divert supplies of propylene, methanol, ammonia, and butane. These are vital for producing solvents and active pharmaceutical ingredients. Low inventories at solvent manufacturers threaten medicine availability. The government is considering quotas to support the pharma sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AkzbDuo
via IFTTT

Read More

Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge generics

Novo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments more accessible to patients. Industry experts believe this will significantly impact competition. Novo Nordisk's established reputation with doctors is also expected to help. The company hopes to gain a larger share of the GLP-1 market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jJXkrHD
via IFTTT

Read More

Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in India

Novo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patient access. These new prices, effective April 1, aim to make the GLP-1 therapies more affordable for individuals managing diabetes and obesity. This move comes as Indian companies launch generic semaglutide following patent expiry, intensifying market competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6dhBEot
via IFTTT

Read More

Lupin gets tentative nod from USFDA for generic Sugammadex injection

Lupin Ltd, a prominent name in the pharmaceutical world, revealed on Tuesday that it has gained tentative approval from the US health authorities for its generic Sugammadex injection. This innovative solution serves to reverse the impacts of muscle relaxants administered during surgeries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SNlPyBz
via IFTTT

Read More

Novo Nordisk plans to cut price of Ozempic as generics hit market

Novo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmakers launched cheaper generic versions of semaglutide. Industry sources suggest Novo's revised price will be competitive. This strategy aims to capture a larger market share against aggressive pricing from Indian companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/raAu7Yq
via IFTTT

Read More

Centre looks to trigger 'Essentials' Act to regulate prices of bulk drugs

The department of pharmaceuticals (DoP) has been holding meetings with the industry executives to take stock of the situation, people in the know said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Vf3cmQN
via IFTTT

Read More

Bankruptcy court admits BSE-listed Supha Pharmachem under Insolvency Resolution Process

The Mumbai bench of the National Company Law Tribunal has admitted Supha Pharmachem into the Corporate Insolvency Resolution Process (CIRP) over a payment default, and appointed Rajesh Jhunjhunwala as interim resolution professional.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JNAOf7X
via IFTTT

Read More

Regulator steps up oversight of GLP-1 drug distribution chain

India's drug regulatory body is intensifying its scrutiny of the distribution channels for GLP-1 weight loss drugs. State drug authorities are directed to ensure stringent compliance with approved protocols and accurate product labeling. Any instances of unauthorized sale or marketing will invite strict legal action. The agency is also keeping a close watch on promotional activities across different platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DuZS9q6
via IFTTT

Read More

Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas Tambe

Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management drug. Biocon aims to become a global medicines company driven by innovation. Insulin remains a strategic anchor. Oncology and immunology are key pillars. New areas like ophthalmology are being explored. Investments will target technology and AI.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rUT1ZgG
via IFTTT

Read More

Zydus Wellness taps Milind Soman as brand ambassador for Glucon-D recharge

Zydus Wellness has appointed actor Milind Soman as the brand ambassador for its new product, Glucon-D Recharge. This marks the company's entry into the performance hydration category. Glucon-D Recharge is designed to help Indians stay active consistently. The product is available in ready-to-drink bottles and sachet sticks. This expansion caters to evolving consumer needs beyond traditional energy powders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SQft7XR
via IFTTT

Read More

India’s urban health alarm: One in five at early heart risk, 25% face respiratory threat

Urban Indians are facing a health crisis. Cardiovascular and respiratory risks are rising. Poor air quality, long commutes, and inactivity contribute to these issues. Many are overweight or obese. Young adults show early warning signs. Early awareness is crucial for health and financial planning. This assessment highlights the combined impact of daily stressors on long-term health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aKnVBAU
via IFTTT

Read More

Painkiller, antibiotic prices set for marginal increase starting April 1

Starting April 1, the prices of essential medicines will experience an increase of 0.6%. This change aligns with the annual alterations in the Wholesale Price Index. Approximately 1,000 medications listed in the National List of Essential Medicines will be impacted.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cx4GEPq
via IFTTT

Read More

US-based Warburg Pincus in talks to buy Maneesh Pharma unit in Rs 1,800 crore deal

US private equity firm Warburg Pincus is nearing a deal to buy Maneesh Pharmaceuticals' non-tuberculosis drug business. The acquisition is valued between ₹1,600 to ₹1,800 crore. This move is part of Warburg's strategy to build a larger pharmaceutical platform in India. A formal announcement is anticipated in the coming months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J6oL8TN
via IFTTT

Read More

Rising costs of key chemicals choke production at drug ingredient makers

India's bulk-drug manufacturers are facing a severe cost crisis as prices of key solvents and intermediates have surged due to supply disruptions linked to the West Asia conflict. This has led to production halts for several units, with paracetamol API prices more than doubling, impacting the entire pharmaceutical value chain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JsMpRqy
via IFTTT

Read More

Centre steps up oversight on GLP-1 drugs amid concerns over 'improper' practices

India's drug regulator is increasing oversight of GLP-1 weight loss drugs. Inspections across 49 entities revealed violations like unauthorized sales and improper prescriptions. Strict actions, including license cancellation, will be taken against non-compliant firms. An advisory also prohibits misleading advertisements. These medications should only be used under qualified medical guidance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YFaK8JV
via IFTTT

Read More

India tightens grip on GLP-1 supply chain amid misuse concerns, expands crackdown on unapproved drugs

India's drug regulator is increasing checks on weight loss drug sales. This action follows inspections of pharmacies and clinics nationwide. The goal is to prevent illegal sales of these specialized medicines. Authorities are also cracking down on unapproved drug combinations. Patient safety is the top priority as regulators enforce rules across the pharmaceutical supply chain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RS4iu8U
via IFTTT

Read More

GST refund stress: MedTech sector flags cash crunch, seeks relief

India's medical device sector is facing severe financial strain, prompting an urgent plea to the government for expedited GST refund processing. Delays in refunds from last year's rate reduction, coupled with rising input costs due to the West Asia conflict, have created significant working capital distress.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xhkNyF1
via IFTTT

Read More

India’s drug regulator flags 90 unapproved FDCs, directs states to take action

India's drug regulator has initiated a nationwide crackdown on unapproved fixed-dose combination drugs. At least 90 such medicines have been identified. States are directed to take immediate action against manufacturers, marketers, and distributors. This move follows lab testing data analysis. The Drugs Controller General of India emphasizes zero tolerance to protect public health and safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x7SGmTb
via IFTTT

Read More

Price alone won't push weight-loss, diabetes drug semaglutide sales: Doctors

Leading drugmakers including Sun Pharmaceuticals, Dr Reddy’s Laboratories, Zydus Lifesciences, Natco Pharma, Eris Lifesciences, USV, Glenmark, and Torrent were among the first to roll out generic semaglutide on the first day of patent expiry of Novo Nordisk’s innovator molecule on Saturday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/my3X8YP
via IFTTT

Read More

India is well positioned to attract future investments, says Eli Lilly's Patrick Johnson

Faster ApprovalsFaster, predictable, and globally aligned clinical trial approvals are critical for India to attract high-value research and strengthen scientific capability and capacityPatrick JohnsonExecutive Vice President of Eli Lilly and Company and President of Lilly International

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SmdTnVf
via IFTTT

Read More

Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 Diabetes

Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to receive DCGI approval for this GLP-1 receptor agonist. Available in 2mg and 4mg strengths, the once-weekly subcutaneous injection demonstrated non-inferior efficacy and a comparable safety profile in Phase III studies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eMFf0PI
via IFTTT

Read More

Natco, Eris Life to launch slimming shots in both Vial and Pen formats

Natco Pharma and Eris Lifesciences are launching generic semaglutide weight-loss injections. The companies are introducing both vial and pen formats. This move aims to make the treatment more affordable. Vials will be available first, targeting a wider patient base. Pens are expected later for metropolitan markets. This strategy offers patients pricing flexibility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wPXzTLW
via IFTTT

Read More

Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expires

Natco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the innovator's drug. The company aims to make this treatment more accessible to patients across India. Other pharmaceutical companies are also preparing to launch their generic versions. This development promises significant cost savings for consumers seeking this medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iSxs32K
via IFTTT

Read More

Natco launches Rs 1,290 semaglutide in India, undercuts diabetes drug prices

Natco Pharma has launched a new generic semaglutide injection in India. This marks a significant step in making advanced diabetes treatment more accessible. The drug is available at a much lower price compared to existing options. This move is expected to benefit a large number of diabetic patients across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/InWTzCi
via IFTTT

Read More

Small pharma companies seek price caps on inputs as costs surge

Indian pharmaceutical units face a severe crisis. Input costs have surged by 200-300 percent. This is due to global conflicts disrupting raw material supply. The Himachal Drug Manufacturers Association seeks government intervention. They want emergency price controls and a crisis task force. This aims to protect the industry and ensure medicine availability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nXC5bIZ
via IFTTT

Read More

Bharat Biotech bets on vaccines to fight drug resistance, eyes post-Covid growth

Hyderabad-based Bharat Biotech is developing novel vaccines to combat antimicrobial resistance (AMR), a significant global health threat. The company aims to administer these vaccines pre-surgery to prevent hospital-acquired infections, addressing a growing need due to rising drug resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ulNcXrk
via IFTTT

Read More

Pharma companies struggle as input costs rise despite 0.6% price hike

Facing a modest 0.6% hike in medicine prices this year, pharmaceutical companies are grappling with the rising costs of raw materials fueled by global unrest. Starting April 1, essential medications such as pain relievers and antibiotics will adjust in price, prompting the industry to appeal to governments for financial relief to manage these escalating expenses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RjCi2NE
via IFTTT

Read More

Chirag Paswan says India working with global bodies on nutraceutical regulations

India is actively working with international regulatory bodies, including Codex Alimentarius Commission, to develop essential regulations for the rapidly expanding nutraceutical sector. The government recognizes the immense growth potential and is committed to addressing existing gaps. This initiative aims to foster a structured environment for the industry's advancement, ensuring nutritional security alongside food security for the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LTHxBrU
via IFTTT

Read More

Zydus’s weight-loss injection to reach India via Lupin partnership

Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide more accessible in India. This collaboration follows the upcoming expiry of Novo Nordisk's patent. Lupin will co-market Zydus's semaglutide injection under its own brand. This move aims to reach more patients across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/duKU36L
via IFTTT

Read More

Zydus, Lupin sign pact to co-market weight-loss Semaglutide injection in India

Zydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and aids in chronic weight management. This collaboration aims to provide advanced therapies for metabolic disorders across the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KkhBqjl
via IFTTT

Read More

SC grills Sebi over lingering probe against Sandesara brothers despite Rs 5,100 cr settlement

In a surprising turn of events, the Supreme Court has scrutinised Sebi's ongoing actions against the directors of Sterling Biotech. This review arises following the directors’ hefty ₹5,100 crore settlement payment. Earlier, the court had invalidated all related cases. Sebi's investigation concerns the suspected routing of funds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cGoaAPK
via IFTTT

Read More

Sun Pharma’s Ilumya expansion bid gets USFDA nod for review

Sun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for treating adults with active psoriatic arthritis. This marks a crucial step for Sun Pharma in expanding its medicine portfolio. The US regulator has accepted the application for review.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3ZMkVv2
via IFTTT

Read More

India pharma production hit by propane shortage; vitamin, hormone supply at risk

India’s pharmaceutical industry is facing the risk of medicine shortages as a propane gas crunch forces several manufacturing units to partially or fully shut operations, disrupting production of key drugs including paracetamol, vitamins and hormones.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zyTPBuk
via IFTTT

Read More

Mankind Pharma targets early Semaglutide launch

Mankind Pharma is set to enter India's semaglutide market soon. The drug's patent expires this month, opening doors for new players. Mankind Pharma plans to offer the medication at affordable prices. This move aims to improve patient access to this important therapy. The company sees a significant opportunity as semaglutide's use extends beyond diabetes to other health areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tyGXjwh
via IFTTT

Read More

Plan afoot to merge 3 Delhi hospitals into single 'super medical hub'

In a revolutionary move for healthcare in Delhi, officials are consolidating Guru Teg Bahadur Hospital, the Delhi State Cancer Institute, and Rajiv Gandhi Super Speciality Hospital into a formidable medical hub. This initiative is not just about maximizing efficiency; it’s about reimagining patient care with cutting-edge resources and comprehensive services at their fingertips.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tQVsLDR
via IFTTT

Read More

Weight-loss drug boom: Will cheaper Ozempic generics shake up India’s fitness and nutrition industry?

The rise of GLP-1 weight-loss drugs such as Ozempic is posing a challenge to the fitness industry, with cheaper generic versions expected to enter India soon. While some fear this could lead to a decline in gym memberships, others see it as an opportunity to offer specialised training and integrated wellness programmes to support people using these medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C0UBNkr
via IFTTT

Read More

Kathua to become India’s antibiotic powerhouse with Rs 600 crore pharma facility

A groundbreaking ceremony led by Union Minister Jitendra Singh has marked the start of a new Rs 600 crore pharmaceutical manufacturing plant in Kathua. This state-of-the-art facility will specialise in producing Amino Cephalosporanic Acid, a vital component of antibiotics. With this investment, India is set to bolster its pharmaceutical sector and lessen dependence on foreign imports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yeDE8hu
via IFTTT

Read More

West Asia war hits medical tourism: Overseas patient flow to Indian hospitals drops up to 75%

Israel-Iran war: Indian hospitals face a sharp decline in international patients. The ongoing conflict has disrupted travel, causing revenue losses. Hospitals report a 50% to 75% fall in overseas patient flows. This situation is prompting a shift towards attracting patients from Southeast Asia, Africa, and Central Asia. Recovery depends on regional stability and travel confidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K07jhvu
via IFTTT

Read More

Ambuja Neotia Group to develop over Rs 700 cr integrated healthcare and hospitality project in Guwahati

Ambuja Neotia Group will build a large integrated healthcare and hospitality project in Guwahati. The Rs 700 crore investment will include a 300-bed multi-speciality hospital and a 4+ star hotel. This initiative aims to boost the region's healthcare infrastructure and economy. The project is expected to create thousands of jobs. It marks the group's second healthcare venture in Assam.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xielzBA
via IFTTT

Read More

'India has intellectual power to be a leader in biomedical innovation,' says Bayer AG

Bayer's CEO Bill Anderson believes India can become a top pharmaceutical market. He highlights the need for supportive policy frameworks, including stronger intellectual property protection. This will attract investment in cutting-edge drugs. India's young population and technological leadership offer significant opportunities. Bayer is investing in innovation centers in Bengaluru, leveraging Indian talent for global missions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kN8cZl1
via IFTTT

Read More

India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

India's drug regulator has issued a stern warning to pharmaceutical companies. Direct or indirect advertising of weight-loss medicines is now prohibited. Obesity awareness campaigns that promote prescription drugs are also under scrutiny. This move comes as global and domestic companies vie for a share of India's growing obesity drug market. The regulator emphasizes that misleading promotions will face action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qvqk8LB
via IFTTT

Read More

India medical device shortage: Polypropylene price surge threatens syringes, IV bags amid Iran war

India's medical devices industry faces a polypropylene shortage due to the Iran war, causing a sharp price increase of over Rs 55 per kg. This surge, coupled with a deepening gas supply crisis impacting syringe production, threatens small and medium enterprises and overall healthcare delivery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jPJiAtX
via IFTTT

Read More

Govt cautions pharma cos against surrogate ads for promoting GLP-1 drugs

Weight loss drug risks: The government has warned of strict regulatory action against those found using surrogate advertising to promote GLP-1 drugs. "A detailed advisory on the use of GLP-1 drugs is expected to be released in the next few days," sources told ET.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9AnrLdw
via IFTTT

Read More

Decoding the antibiotic resistance crisis: How everyday habits can save our strongest medicines

Antibiotics are losing their power as germs grow stronger, a crisis fueled by everyday misuse. Experts urge parents to rethink treating minor ailments and fevers without medical advice. Preventing infections through simple hygiene practices like handwashing and sanitizing surfaces, summarized by the S.H.A.K.E. formula, is crucial to preserving these life-saving medicines for future generations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3diYcxA
via IFTTT

Read More

Raw nerve: Drugs may get costlier as prices of ingredients surge 30%

India's medicine prices are poised for a sharp increase due to a 30% surge in raw material costs, driven by container ship scarcity following the Iran war. This scarcity is hindering the movement of crucial ingredients from China, impacting local manufacturing and potentially forcing producers to pass on higher expenses to consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tk2Gyhv
via IFTTT

Read More

India's exports of active pharma ingredients at Rs 41,500 cr surpassed imports in FY25

With API exports hitting an impressive Rs 41,500 crore last fiscal year, India has outperformed its imports of Rs 39,215 crore. The government is pushing for a self-reliant economy via the Production Linked Incentive scheme, strategically aimed at cutting down import connections, notably with China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qGlBJYv
via IFTTT

Read More

Pharma exporters seek freight sops and logistical support as costs rise

As tensions in West Asia escalate, Indian pharmaceutical exporters are grappling with surging costs. In response, Pharmexcil is advocating for government interventions, including freight subsidies and enhanced logistical support. Meanwhile, companies are pivoting towards alternative shipping routes and ramping up their buffer stocks in anticipation of potential disruptions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HAW7DLB
via IFTTT

Read More

Looking beyond seasonal sniffles: Protecting children's immunity from climate instability

Climate change is disrupting traditional illness patterns, affecting children's health. Savlon Swasth India Mission promotes proactive hygiene with the S.H.A.K.E. formula. This strategy encourages sanitizing, handwashing, doctor consultations, wound care, and nutritious meals. These habits build resilience against unexpected illnesses. The mission has positively impacted millions of children through hygiene education programs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EbVX8jG
via IFTTT

Read More

Cipla USA recalls Nilotinib anti-cancer capsules over manufacturing issue: USFDA

Cipla USA is recalling over 400 cartons of its generic anti-cancer drug Nilotinib Capsules (150 mg and 200 mg) due to a manufacturing issue, the US Food and Drug Administration has said. The recall affects specific batches distributed in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zEldipu
via IFTTT

Read More

HLL Lifecare to expand AMRIT Pharmacies to 550 outlets by 2027

HLL Lifecare will significantly expand its AMRIT pharmacy network across India. The number of outlets will more than double to over 550 by December 2027. This initiative aims to make life-saving medicines and implants more affordable and accessible. Special focus will be on underserved and remote regions. The expansion involves an investment of Rs 100 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5SmdnUW
via IFTTT

Read More

India set to lead global homoeopathy with certified quality frameworks: Experts

India is set to lead the global homoeopathy market. Strong clinical expertise and practitioner networks are driving this growth. Internationally recognised quality certifications like AYUSH Premium Mark and NABL accreditation are key. Indian brands are now well-positioned to challenge established European dominance. This marks a significant shift in the global homoeopathy landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pObwAGH
via IFTTT

Read More

Middle East conflict hits medical tourism, Indian hospitals tap other markets

Indian hospitals are diversifying patient sources to Southeast Asia, Africa, and Central Asia as the Middle East conflict disrupts medical travel. This shift aims to mitigate revenue losses from the region, which contributes significantly to their medical value travel earnings. Hospitals are also enhancing teleconsultation services and seeking government support for direct flights to maintain patient inflows.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7cAkRfo
via IFTTT

Read More

Cipla recalls over 400 cartons of cancer drug in US: FDA

Cipla USA is recalling over 400 cartons of its anti-cancer drug Nilotinib Capsules. The recall is due to a manufacturing issue where the capsules failed to meet specifications. This is a voluntary Class III recall, meaning it is not expected to cause adverse health consequences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tdnVDy3
via IFTTT

Read More

FDA official overseeing vaccines resigns amidst controversy

A key US Food and Drug Administration official responsible for vaccines is departing at the end of April. Vinay Prasad faced criticism for health policy decisions, particularly concerning Covid-19 vaccine efficacy. His exit follows controversies, including refusing to review a flu vaccine application. Prasad had previously raised doubts about Covid-19 vaccine safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5WejPXN
via IFTTT

Read More

Key drug prices may surge on hoarding and higher demand

Escalating Middle East conflict is expected to increase demand for essential medicines. This surge could lead to higher drug prices, potentially benefiting Indian pharmaceutical manufacturers. Companies are monitoring the situation closely. Increased demand for chronic and acute therapy drugs is anticipated. Indian firms may see export disruptions but also higher overall demand if the conflict extends.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S615dwf
via IFTTT

Read More

Obesity & diabetes are world's next health "tsunami", warns ebola discoverer Peter Piot

A leading virologist warns of a global tsunami of obesity and diabetes, surpassing viral threats. India faces significant vulnerability as diabetes rates surge. While pandemic preparedness has improved technically, societal trust remains a challenge. Innovations like new anti-obesity drugs offer hope but require broader access and lifestyle changes. India should prioritize discovery and innovation in biopharma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kTQ8t5R
via IFTTT

Read More

Pharma exports may take up to $500 million hit as freight costs rise

India's drug exports face a significant threat from the Iran war. Higher freight costs and shipping companies avoiding Gulf routes could impact shipments worth $300-500 million. This disruption affects both raw material imports from China and finished product exports to West Asia and beyond. Companies are building inventories to manage potential delays.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ibVD5SK
via IFTTT

Read More

India & China must-win markets on rising middle-class households: Reckitt Chief

Reckitt Benckiser sees India and China as vital growth markets. The company's CEO highlighted the expanding middle class in these nations. Emerging markets are driving Reckitt's revenue expansion. India and China showed strong growth in the last quarter. This performance helped offset weaker results in developed markets. Reckitt aims to increase its reach in India through improved distribution.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/90FKEjL
via IFTTT

Read More

Iran war could disrupt India’s pharma exports by up to $500 million

The Iran war is impacting India's drug exports. Higher freight costs and shipping refusals to Gulf hubs are causing concern. Industry estimates suggest a potential loss of $300-$500 million. While manufacturing remains unaffected, logistics are complicated. Companies are maintaining inventories to ensure supply continuity. The situation could lead to temporary supply challenges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j9pxiSV
via IFTTT

Read More

India pharma exports risk disruption if Middle East conflict widens

Indian drug exports face significant challenges. A wider Middle East conflict could disrupt vital shipping routes. This may lead to longer transit times for temperature-sensitive medicines. Increased freight costs and potential delays in key markets like the UAE and Saudi Arabia are also concerns. Air cargo routes are also at risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LhIpoxs
via IFTTT

Read More

Urban India faces metabolic health crisis as 73 million are overweight or obese

In India's vibrant urban landscape, obesity and diabetes are becoming formidable adversaries. A new analysis highlights that while countless individuals are caught in the grip of these health challenges, there's a startling lack of awareness about innovative GLP-1 weight loss medications. Interestingly, informed individuals express considerable eagerness to explore these options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35PxcKE
via IFTTT

Read More

Ahead of its time, a GLP-1 drug almost made it out of India

Fifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes management and weight loss. Unfortunately, due to prohibitive clinical trial costs and a skeptical outlook on the obesity market, Zydus chose to shelve further development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bFBIjhY
via IFTTT

Read More

Child hears again 18 months after brain stem implant at AIIMS

A young boy in India has received a groundbreaking auditory brain stem implant. This marks a first for AIIMS. The surgery was performed after conventional implants were not suitable. The child is now responding to sounds and speaking more clearly. Doctors highlight the importance of early detection for hearing loss.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DiS2nva
via IFTTT

Read More

NATCO Pharma launches generic blood cancer treatment medicine in US

NATCO Pharma has launched generic Pomalidomide capsules in the US. This drug treats blood and bone marrow cancer. It is a generic version of Celgene's Pomalyst. The launch is in partnership with Breckenridge Pharmaceutical. This move aims to make specialty medicines accessible. It offers an affordable solution for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/845bQ6z
via IFTTT

Read More

Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave

Eli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite its premium pricing, even as lower-cost semaglutide generics prepare to enter the Indian market.Winselow Tucker, president and general manager of Eli Lilly and Company (India), told ET that the company sees room for both branded innovator drugs and generics to thrive simultaneously in the rapidly expanding domestic segment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ks8Hj03
via IFTTT

Read More

All our AI models have scientists in loop, says MSD chief AI officer

MSD's Chief AI Officer, Anton Groom, highlights AI's transformative role in drug discovery. AI models like TEDDY and KERMT are assisting scientists, identifying new drug targets and refining lead identification. This technology is accelerating the development of new medicines, with two AI-discovered molecules already in clinical trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/utByhpW
via IFTTT

Read More

Brain can keep producing new neurons in old age, but Alzheimer’s may disrupt the process: Study

New research reveals the adult brain generates fresh nerve cells in the hippocampus, vital for memory. This ability declines in Alzheimer's patients. Scientists observed this process in postmortem brain samples. Healthy older adults show continued neuron production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CarbWi1
via IFTTT

Read More

ACC clears Dr Rajeev Singh Raghuvanshi’s reappointment as Drugs Controller (India)

Dr Rajeev Singh Raghuvanshi will continue as Drugs Controller (India) at CDSCO. His reappointment is on a contract basis for one year starting March 1, 2026. This decision follows a proposal from the Department of Health and Family Welfare. Dr Raghuvanshi heads the CDSCO, responsible for drug quality and new drug approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8FeGzSH
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod to market generic drugs

Zydus Lifesciences has won regulatory clearance in the United States to launch generic Ivermectin and Dapsone tablets. Used to treat parasitic worm infections and leprosy, the approval signals progress in the company's US growth strategy and broadens its market footprint.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mQ4rfo7
via IFTTT

Read More

Abbott signs pact with Novo Nordisk to offer semaglutide

Semaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic drug makers has already lined up the launch of their generic semaglutide drugs immediately after the patent expiry, prompting the company to brace up for the upcoming competition in the GLP-1 market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SUgAmZw
via IFTTT

Read More

Lupin receives USFDA EIR for Goa facility with VAI status

Drug maker Lupin said it has received an Establishment Inspection Report from the US Food and Drug Administration for its Goa-based manufacturing facility, with a Voluntary Action Indicated classification following a November 2025 inspection.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rp3wNg6
via IFTTT

Read More

India moves closer to dengue vaccine as final trials underway

An Indian vaccine candidate, DengiAll, is in its final testing phase. This single-dose shot offers hope against the deadly dengue disease. Over 10,000 volunteers are participating in the trials. If successful, DengiAll could be available next year. This development is crucial for India and other lower-middle-income countries facing rising dengue cases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4RBklXJ
via IFTTT

Read More

Dräger India collaborates with Breach Candy Hospital to advance clinical education

Dräger India and Breach Candy Hospital have partnered to enhance clinical education and skill development for healthcare professionals. This collaboration brings the Dräger Medical Academy to Mumbai, offering digital learning modules and VR-based simulation training to bridge skill gaps and improve patient safety. The initiative aims to foster continuous learning and readiness in India's evolving healthcare landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n4tzOLc
via IFTTT

Read More

Navigating environmental shifts: How proactive hygiene shapes a child's future

In today's unpredictable climate, raising children requires a proactive approach to health beyond traditional methods. Savlon Swasth India Mission's podcast, The Doc's Pod, emphasizes science-backed hygiene practices as a strategic tool for physical empowerment. By integrating habits like regular handwashing and surface sanitization, families can build a robust foundation for enduring health and cognitive development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nha8Qw1
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic drug

Alembic Pharmaceuticals has secured approval from the US health regulator for a generic seizure medication. The company received final clearance from the USFDA for Lamotrigine orally disintegrating tablets. This drug is therapeutically equivalent to GlaxoSmithKline's Lamictal. It is used for various seizure types in patients aged two and older. The market for this medication is estimated at USD 27 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1U7YSVz
via IFTTT

Read More

Zydus plans launch of semaglutide generic in reusable pen form

Zydus Lifesciences is set to launch a generic version of the weight-loss injection semaglutide next month. The drug will be available under brand names Semaglyn, Mashema, and Altreme. Zydus will offer a unique reusable pen for easier dosage adjustment. This move aims to simplify treatment for patients managing Type 2 diabetes and obesity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fEWJ2gU
via IFTTT

Read More

GST department initiates inspection and search ops at Lupin's office

Maharashtra's Goods & Services Tax Department has initiated inspection and search proceedings at Lupin's registered office. The pharmaceutical giant stated that these actions will not impact its financials, operations, or other activities. Lupin recently reported strong Q3 FY26 growth, with highest-ever US sales and double-digit growth in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/raeUq9M
via IFTTT

Read More

India’s weight-loss drugs to get cheaper as semaglutide patent expires

Affordable generic versions of popular weight-loss drugs Wegovy and Ozempic are set to launch in India. This follows the patent expiry of semaglutide, the key ingredient. Several Indian pharmaceutical companies are preparing for a March 21 launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GcepZab
via IFTTT

Read More

Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say

Dr Reddy's Laboratories is poised to launch its generic semaglutide injection, potentially named Obeda, in India by March. This move anticipates the March 2026 patent expiry for the active ingredient in Novo Nordisk's Ozempic and Wegovy. The Indian drugmaker plans competitive pricing, aiming to capture a significant share of the growing diabetes and obesity market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rkOETu6
via IFTTT

Read More

Merck & Co to create a separate cancer unit as patent cliff looms

Merck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-growing medicines as the blockbuster cancer therapy Keytruda nears patent expiration. The company plans to emphasize newer products, including a pneumonia vaccine and a treatment for lung disease, as key drivers of its next growth phase.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GvSQanm
via IFTTT

Read More

Drug regulator cracks down hard on non-compliant cough syrup makers

Authorities are cracking down on hundreds of cough syrup manufacturers failing quality checks. This action follows tragic deaths linked to toxic ingredients. Inspections are ongoing, with strict measures like unit closures and license cancellations being implemented. The drug regulator aims to eliminate substandard cough syrup production. Manufacturers must adhere to new quality standards or face closure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lFP34rK
via IFTTT

Read More

Government urges pharma sector to anchor global supply chains via quality, innovation

Union Minister J P Nadda urged India's pharmaceutical industry to lead global supply chains with quality and innovation. India is embracing new technologies for disease detection and diagnostics. Initiatives like Biopharma Shakti and PRIP are boosting manufacturing and research. The nation is committed to regulatory excellence and aligning with global standards. A quality-first approach is key to sustained global competitiveness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1Zd4mrz
via IFTTT

Read More

India's drug regulator inspected 90% of cough syrup makers, found lapses, official says

India’s pharmaceutical regulator has launched a thorough inspection of cough syrup manufacturers, discovering several discrepancies in their operating procedures. This decisive action follows alarming reports of child deaths linked to these syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GxY9vwT
via IFTTT

Read More

Biosimilars & innovation are Dr. Reddy’s growth pill: Generics to remain core business, says co-Chairman & MD GV Prasad

Dr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimilars, anticipating significant growth within five years. Generics and active pharmaceutical ingredients will continue to be major revenue sources. Dr Reddy's aims to compete in a biologics-led future by investing in research and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vAW1EzD
via IFTTT

Read More

Expects Pen-G production capacity to touch 10k metric tonnes in 12 months: Aurobindo Pharma

Aurobindo Pharma is set to boost Penicillin-G output to over 10,000 metric tonnes annually. Its China manufacturing facility is projected to reach EBITDA break-even this quarter. The company is also advancing its US operations and developing complex generics. These strategic moves aim for sustainable growth and improved profitability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sdLF4H2
via IFTTT

Read More

BahiaFarma, Biocon, Bionovis inks MoU in pharma sector

India and Brazil signed multiple Memoranda of Understanding (MoUs) during Brazilian President Lula da Silva's visit. Key agreements include a pact for developing a breast cancer medicine, cooperation in iron ore blending at Gangavaram Port, and R&D in strategic pharmaceutical ingredients. ApexBrasil and FICCI also agreed to boost trade and investment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PnhsZ48
via IFTTT

Read More

Quality Care India plans to invest Rs 600 crore to set up healthcare facility in Nagpur

Quality Care India Limited is set to invest Rs 600 crore in a new 350+ bed multi-speciality hospital in Nagpur. The facility, to be developed on Maha-Metro land near Kasturchand Park Metro Station, aims to strengthen healthcare infrastructure in Central India. This project, a public-private partnership, is expected to create over 1,500 jobs and enhance regional healthcare capacity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9QZqgoM
via IFTTT

Read More

Novartis exits India arm, ChrysCapital-led group buys 70.68% stake for ₹1,446 crore

Swiss drugmaker Novartis AG is selling its 70.68% stake in its Indian unit for Rs 1,446 crore to a consortium led by ChrysCapital. This divestment aligns with Novartis' strategy to become a pure-play innovative medicines company, while it maintains a significant presence in India through its wholly owned subsidiary.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0hWX6Y8
via IFTTT

Read More

Drugmakers flag concerns over blue-strip antibiotic labels

The government mandated a blue line on antibiotic packaging to curb misuse. However, pharmaceutical companies argue this will disrupt operations and finances. They believe the measure lacks scientific backing and global alignment. Industry associations are urging the government to withdraw the notification. Existing regulations already address antimicrobial resistance concerns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GuhQOfs
via IFTTT

Read More

ChrysCapital, two others launch open offer for Novartis India

A consortium including WaveRise Investments, ChrysCapital, and Two Infinity Partners is set to acquire a significant stake in Novartis India. This move is part of Novartis's strategy to divest its stake. The transaction is expected to conclude in the third quarter of 2026. Novartis will continue its operations in India through Novartis Healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lQVLZwt
via IFTTT

Read More

Indian drugmaker Sai Life Sciences to boost headcount by about 20% amid global demand upswing

Sai Life Sciences will boost its workforce by over 700 employees next financial year. This expansion supports growing global demand for its services. The company is increasing capacity to meet this demand. New hires will focus on scientific, technical, and management roles. This move reflects a broader trend of global pharma companies expanding in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ExMusJk
via IFTTT

Read More

Thyroid, antibiotic drugs face fresh safety warnings after national review

New safety warnings are coming for two common medicines, doxycycline and carbimazole. Indian drug regulators have identified potential mental health side effects for doxycycline. Carbimazole will now carry stronger warnings about a rare but serious blood disorder. Manufacturers must update prescribing information. These changes aim to improve patient safety by highlighting important risks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H09vWqY
via IFTTT

Read More

Zydus launches biosimilar for ophthalmic care

Zydus Lifesciences has introduced Anyra, its first indigenously developed biosimilar for the treatment of visual impairment in India. This innovative drug, akin to Aflibercept 2 mg, addresses vision loss resulting from diseases like diabetes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eCiGEwj
via IFTTT

Read More

Pharma firms asked for side-effects of common medicines

India's drug regulator has issued new safety warnings for common medicines. Doxycycline, an antibiotic, will now list side effects like anxiety and dizziness. Carbimazole, used for thyroid issues, will highlight the risk of a life-threatening condition called agranulocytosis. Manufacturers must update package inserts and promotional materials. These changes follow recommendations from pharmacovigilance experts to ensure patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QCPknbg
via IFTTT

Read More

Warburg Pincus talks in final lap to buy Integrace Health for Rs 1,200 crore

Integrace is currently owned by homegrown PE fund True North and Singapore sovereign investor Temasek Holdings. True North Fund VI LLP holds a 55.83% stake in Integrace, while Temasek arm V-Science Investments Pte owns 43.91%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t7hfmGZ
via IFTTT

Read More

Steroid abuse among gym-goers raises heart, liver risks; issue raised in Parliament

Young people are facing severe health issues due to steroids and unsafe supplements. Doctors report liver toxicity, infertility, and aggression. Heart specialists warn of life-threatening consequences like heart attacks. Mental health experts note links to depression and anxiety. The market for these substances requires stricter checks and greater awareness among youth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HaBfwyV
via IFTTT

Read More

Seeing with sound: AIIMS distributes AI-powered smart glasses to help visually impaired

AIIMS has equipped 53 visually impaired individuals with advanced AI-powered smart vision glasses, transforming their environments into audible guidance. This innovative project empowers both children and adults to navigate life with newfound independence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yZ6uDUx
via IFTTT

Read More

AI can address health inequities, but cannot replace human touch: Union MoS Health Anupriya Patel

Speaking at the AI Impact Summit in the national capital, Patel asserted that India's governance model positions AI as an enabler and force multiplier, bringing the country closer to the goals of inclusivity and health equity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3wjVESA
via IFTTT

Read More

29 vitamin-mineral FDC drugs under review for possible ban over 'irrational' tag

A looming ban on twenty-nine vitamin and mineral combination drugs has sparked a heated debate. Initially flagged as irrational by an expert panel in 2015, these products are now being re-evaluated by a specialized sub-committee. Before any final ruling, the companies will be given a chance to defend their products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eWhaIyb
via IFTTT

Read More

Lupin signs supply deal to launch antidepressant in Canada

Drug firm Lupin has partnered with Spektus Pharma. They will commercialise the antidepressant DeslaFlex in Canada. This collaboration combines Lupin's Canadian presence with Spektus's formulation expertise. It aims to offer patients more personalized care for Major Depressive Disorder. The deal strengthens Lupin's central nervous system portfolio. Lupin shares saw a slight increase on Monday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kMS69A4
via IFTTT

Read More

Alkem Labs' Chakan facility gets six observations in USFDA inspection, no data integrity issues

Alkem Laboratories announced its subsidiary Enzene Biosciences received a Form 483 from the USFDA. The inspection at the Chakan manufacturing unit resulted in six procedural observations. The company highlighted zero observations related to data integrity. Enzene is preparing its response to the USFDA within the given timeline. Corrective actions are also being initiated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uRrOng6
via IFTTT

Read More

Govt looks to provide access to AI resources to medical students: Official

The government plans to give medical students access to e-books and AI tools. This initiative will begin with 57 government medical colleges in smaller towns and rural areas. The aim is to improve students' skills by providing better access to digital and AI-powered learning materials. The program will gradually expand to include private colleges later.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PVv2AMH
via IFTTT

Read More

Adven Biotech says it's India's first homeopathic brand to get NABL certification

Adven Biotech achieves a significant milestone as India's first homeopathy brand to earn NABL certification. This accreditation underscores India's commitment to global healthcare standards in the Ayush sector. The certification validates Adven's quality control and testing laboratories, aligning with Prime Minister Modi's vision for Ayush. It aims to boost confidence and expand the global acceptance of Indian homeopathy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zTj9iAE
via IFTTT

Read More

GST rejig marks key shift towards making cancer care affordable, AIIMS researchers says

AIIMS researchers highlight recent GST reforms, including tax exemptions on cancer drugs and medical equipment, aiming to make cancer care more affordable. Increased taxation on tobacco products is also noted as a positive step for public health and revenue generation for cancer initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g7EB8Ql
via IFTTT

Read More

India becoming backbone of global clinical research

India has emerged as a key player in international clinical trials, showcasing resilience even in the face of global hurdles. With research and innovation on the rise, firms like Parexel recognize India's crucial contribution to ensuring consistent business operations. Instead of threats, artificial intelligence presents avenues for professionals to expand their roles and skillsets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZivtCy1
via IFTTT

Read More

Alkem Labs unit to buy up to 55% of Occlutech for $118 million

Alkem Laboratories is entering the advanced cardiovascular devices market. Its medical devices unit will acquire a significant stake in Switzerland's Occlutech Holding. This strategic move aims to access high-value global markets. The deal is expected to finalize by June 2026. Occlutech is a key player in Europe's minimally invasive cardiac implants.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QRcUVtm
via IFTTT

Read More

AIIMS Delhi first in country to announce launch of face transplant programme

AIIMS New Delhi has become the first hospital in India to introduce face transplantation, a complex reconstructive procedure for patients with severe facial deformities. The Department of Plastic, Reconstructive and Burns Surgery has begun creating a patient registry and is conducting specialised training, including a cadaveric workshop, with support from international expert Dr Indranil Sinha of Harvard Medical School.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zHdnsOB
via IFTTT

Read More